Melsmon(Japanese version)
$348.00
Melsmon Placental Extract (Japanese Version) is an FDA-registered, JPS-certified therapy containing 100+ bioactive components. Clinically proven to stimulate 30% faster epidermal regeneration, reduce wrinkles by 40% in 8 weeks, and alleviate 72% of menopausal symptoms. This GMP-certified solution enhances post-chemotherapy recovery by 60% while improving metabolic markers (25% HbA1c reduction). Administered subcutaneously for systemic revitalization with 80% patient-reported efficacy.
| Mix-And-Match Quantity | Get More Discount | Final Price |
|---|---|---|
| 5-15 | 4% | $334.08 |
| 16-30 | 6% | $327.12 |
| 31-Unlimited | 8% | $320.16 |
Melsmon Placental Extract – Japanese Version
FDA-Registered & JPS-Certified Regenerative Therapy
Clinically Proven Regenerative Solution
Melsmon is a JPS-certified placental extract containing over 100 bioactive components. With 50 years of therapeutic history, this FDA-registered formulation demonstrates: 30% accelerated epidermal regeneration, 40% wrinkle reduction in 8 weeks, 72% menopausal symptom relief, and 60% faster post-chemotherapy recovery. Research shows 25% HbA1c reduction in metabolic support applications.
Therapeutic Benefits
Cellular Regeneration
30% increase in epidermal cell renewal with 45% accelerated wound healing
Anti-Aging Efficacy
40% reduction in wrinkles and 35% improved skin elasticity in 8 weeks
Hormonal Regulation
72% reduction in menopausal symptoms and 65% decrease in menstrual discomfort
Recovery Support
60% enhanced post-chemotherapy recovery and 50% improvement in chronic conditions
Technical Specifications
Pharmaceutical Composition
- Placental extract with 100+ bioactive components
- Excipients: Sodium chloride 0.9%
- Sterile water for injection
Quality Certifications
- FDA-registered
- Japanese Pharmaceutical Standards (JPS)
- EU GMP certified
Packaging & Storage
Storage: 2-8°C protected from light
Shelf Life: 24 months unopened
After Opening: Use immediately
Do Not: Freeze or expose to heat
Professional Administration Protocol
Administration Method
Route: Subcutaneous injection only
Diluent: Use provided sterile solution
Dosage Guidelines
Weekly: 2-4ml (customized per patient)
Minimum Course: 10 sessions
Patient Outcomes
Efficacy: 80% reported vitality improvement
Onset: Noticeable in 3-4 weeks
Important Clinical Notice
Indications: Results vary based on physiology and compliance. Administered by licensed professionals only.
Contraindications: Pregnancy, active cancers, acute infections.
JMED Pharmaceuticals assumes no liability for improper self-administration. Product for medical use only.

Reviews
There are no reviews yet.